冠状病毒给不同的卫生系统带来了巨大的支出负担。疫苗接种计划,对抗大流行疾病的关键解决方案,被称为预防和控制流行病的安全有效干预措施。我们的目标是进行系统审查,为全球所有卫生政策制定者提供经济证据,证明可用于对抗新冠肺炎的不同类型疫苗的价值。
■在Medline/PubMed上进行的电子搜索,科克伦图书馆,WebofScience,Scopus,Embase,和其他经济评价数据库。相关和已发表的文章在2022年3月之前通过使用“疫苗接种”等关键字进行搜索,\"\"Covid-19,\"\"成本效益,“”成本效用,\"\"成本效益,经济评估,“和”经济评价。“其次是根据纳入和排除标准选择最合适的文章,捕获的数据和提取的结果。通过CHEERS2022的清单对文章进行的质量评估。最后,审查中包括13篇文章。
所有信使RNA疫苗均占主导地位,在初级疫苗接种计划中,除了一项研究增强作用外,没有接种疫苗的覆盖率约为70%。从付款人的角度来看,从社会的角度来看,投资于疫苗的一美元的利润会更低。因此,初级大规模疫苗接种可以被认为是初级疫苗接种中具有成本效益的干预措施,可以挽救更多的生命并产生更多的积极外部效应。然而,当考虑到统计寿命值和全球经济和教育劣势时,所有疫苗的成本效益比都会增加.
■区域疫情中的COVID-19主要疫苗接种计划,从长远来看,将显示出可观的成本效益。有人建议,由于疫苗接种的正外部性,初级大规模疫苗接种,在COVAX-19TM的帮助下,与世界各地的个人生命损失以及经济和教育干扰相比,可以被认为是抗击病毒流行的可靠方法。
UNASSIGNED: Coronavirus has burdened considerable expenditures on the different health systems. Vaccination programs, the critical solution against pandemic diseases, are known as safe and effective interventions to prevent and control epidemics. We aimed to perform a systematic
review to provide economic evidence of the value of different types of vaccines available to combat the Covid-19 to all health policymakers worldwide.
UNASSIGNED: Electronic searches conducted on Medline/PubMed, Cochrane Library, Web of Science, Scopus, Embase, and other economic evaluation databases. Related and published articles searched up to March 2022 by using keywords such as \"Vaccination,\" \"Covid-19,\" \"Cost-benefit,\" \"Cost-utility,\" \"Cost-effectiveness,\" \"Economic Assessment,\" and \"Economic evaluation.\" Followed by choosing the most suitable articles according to inclusion and exclusion criteria, data captured and the results extracted. The quality assessment of the articles performed by the checklist of CHEERS 2022. Finally, 13 articles included in the
review.
UNASSIGNED: All messenger RNA vaccines were dominant with approximately 70% coverage against no vaccination in the primary vaccination program except in one study that looked at booster effects. From a payer\'s perspective, a dollar invested in a vaccine would be less profitable than from a societal perspective. Therefore, primary mass vaccination can be considered a cost-effective intervention in primary vaccination to save more lives and produce more positive externalities. However, the cost-benefit ratio for all vaccines increases when statistical lifetime value and global economic and educational disadvantages are considered.
UNASSIGNED: The COVID-19 primary vaccination programs in regional outbreaks, from a long-term perspective, will demonstrate substantial cost-effectiveness. It is suggested that due to the positive externalities of vaccination, primary mass vaccination, with the help of COVAX-19TM, could be considered a reliable way to combat viral epidemics compared to the loss of individual lives and economic and educational disturbances around the world.